What are the risks of low‑dose naltrexone (LDN) therapy in the pediatric population?

Low-Dose Naltrexone Safety in Pediatric Patients

The FDA explicitly states that the safe use of naltrexone in pediatric patients younger than 18 years old has not been established, making low-dose naltrexone (LDN) an off-label therapy with limited pediatric safety data. 1

Primary Safety Concerns

Lack of Established Pediatric Safety Profile

The most critical issue is that naltrexone lacks FDA approval for any pediatric indication, regardless of dose. The drug label clearly warns that safety in children under 18 has not been established 1. This means LDN use in children represents off-label prescribing with inherent uncertainty about age-specific risks.

Specific Risks in Children

Hepatotoxicity Risk:

• Naltrexone causes dose-dependent hepatocellular injury, demonstrated in studies using higher doses (up to 300 mg/day) 1
• While LDN uses substantially lower doses (typically 0.5-5 mg), the hepatotoxic potential in developing pediatric livers remains incompletely characterized
• Children require baseline liver function testing and ongoing monitoring, though no pediatric-specific monitoring protocols exist 1

Opioid Antagonism Complications:

• LDN can precipitate severe withdrawal in any child with occult opioid exposure 1
• This is particularly concerning given that 7.2 million outpatient opioid prescriptions were dispensed to U.S. children in 2009, with frequency doubling over the preceding decade 2
• Children may not reliably report opioid use (prescribed or otherwise), increasing withdrawal risk
• If a child on LDN requires emergency opioid analgesia, substantially higher opioid doses may be needed, risking deeper and more prolonged respiratory depression 1

Neuropsychiatric Effects:

• Depression and suicidal ideation have been reported with naltrexone, though causality is unclear 1
• The FDA label specifically warns about these risks and recommends family notification 1
• Pediatric patients may be particularly vulnerable given developmental brain changes and difficulty articulating mood symptoms

Other Common Adverse Effects:

• Nausea (10%), headache (7%), dizziness (4%), nervousness (4%), fatigue (4%), insomnia (3%) 1
• Transient sedation is most commonly reported in pediatric studies 3
• Vivid dreams, drowsiness, and gastrointestinal symptoms occur frequently 4

Limited Pediatric Evidence Base

The available pediatric data comes from small, short-term studies:

Crohn's Disease Study:

• Only 14 children (ages 8-17) studied with LDN 0.1 mg/kg for 8 weeks 5
• No serious adverse events occurred, but sample size and duration were insufficient to detect rare or delayed toxicities
• This represents the most robust pediatric LDN safety data available

Autism Spectrum Disorder:

• Studies used doses of 0.5-2 mg/kg/day 3
• Transient sedation was most common adverse effect
• No serious adverse effects reported in short-term studies, but methodological limitations (small samples, short duration, inconsistent evaluation) severely limit conclusions 3

General Limitations:

• Most pediatric evidence consists of case reports and small case series 6, 3
• Publication bias likely favors positive results
• Long-term safety data in children are essentially nonexistent
• Developmental pharmacokinetic and pharmacodynamic changes in children are poorly characterized for naltrexone 6

Critical Clinical Considerations

Before Prescribing LDN to Any Child:

1. Verify complete opioid freedom for at least 7-10 days to avoid precipitated withdrawal 1
2. Obtain baseline liver function tests and establish monitoring schedule 1
3. Screen for depression/suicidal ideation and establish safety monitoring plan 1
4. Educate family that child is taking naltrexone and to report any mood changes immediately 1
5. Document informed consent acknowledging off-label use and lack of established pediatric safety 1
6. Ensure child has medical alert identification warning that higher opioid doses may be needed in emergencies 1

Contraindications:

• Any current opioid use or dependence (absolute contraindication) 1
• Acute hepatitis or liver failure 1
• Anticipated need for opioid analgesia 1

Bottom Line

LDN should only be considered in pediatric patients after failure of multiple evidence-based therapies, with explicit acknowledgment that safety is not established and the child is receiving experimental treatment. The risk-benefit calculation must account for the severity of the underlying condition, availability of alternative treatments, and family understanding of the uncertain safety profile. Recent comprehensive reviews conclude that current evidence does not support routine clinical use of LDN, even in adults, due to lack of replication of early positive findings in controlled trials 7.